June 9th 2023
Findings from the phase 3 PhALLCON trial show that ponatinib plus reduced-intensity chemotherapy could be a new standard of care for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
February 27th 2023
MRD Reported Undetectable After Liso-cel CAR T-cell Therapy in CLLAugust 2nd 2019
In the phase I/II TRANSCEND CLL 004 study, chimeric antigen receptor T-cell therapy lisocabtagene maraleucel led to undetectable minimal residual disease in patients with relapsed/refractory chronic lymphocytic leukemia.
Combination Therapies Potentially Address Controversies Over Optimal AML ManagementJuly 25th 2019
In an interview with Targeted Oncology, Richard M. Stone, MD, discussed the biggest controversies across a number of patient populations in AML. He also highlighted some areas of research he finds particularly exciting for the treatment of patients with AML.
Rituximab Biosimilar Approved by FDA for CD20+ B-Cell NHL and CLLJuly 23rd 2019
PF-05280586, a biosimilar for rituximab, has been approved by the FDA for use as a single-agent or in combination with chemotherapy for the treatment of adult patients with CD20-positive B-cell non-Hodgkin lymphoma, or in combination with chemotherapy for patients with CD20-positive chronic lymphocytic leukemia.
Advancements in Frontline AML Treatment Could Lead to Better Patient OutcomesJuly 23rd 2019
Over the past 2 years, the amount of FDA-approved frontline treatments for patients with acute myeloid leukemia have increased. These emergent treatments have caused a shift in the standard of care for patients with AML and inspiring analyses of regimens that researchers believe can improve outcomes for AML treatment.
Survival Improvement Seen With Gilteritinib Across FLT3-ITD+ AML Subgroup AnalysesJuly 19th 2019
In an interview with Targeted Oncology, Mark J. Levis, MD, PhD, discussed the findings from the follow-up analyses of the ADMIRAL trial that were presented at the 2019 ASCO Annual Meeting. He explained what these findings mean for the patient and what questions future research will aim to answer.
Discussing Reimbursement Barriers for FLT3 Mutation AnalysisJuly 11th 2019
<em>FLT3</em> mutation analysis in laboratories has brought on reimbursement barriers in clinical oncology. Jordan Clark, chief commercial officer, Diaceutics, a diagnostic development and commercialization company, spoke to <em>Targeted Oncology</em> about the cause of reimbursement issues and how the problem affects all parties involved.
Continued Benefit Seen With Acalabrutinib and Obinutuzumab Combo in CLLJuly 3rd 2019
At 3 years of follow-up, the combination of acalabrutinib and obinutuzumab continued to show benefit in patients with both newly diagnosed chronic lymphocytic leukemia and relapsed or refractory disease.
Examining BTK Inhibition As A Superior Treatment for Relapsed/Refractory CLLJuly 3rd 2019
Addressing the need for treatments that are more effective and less toxic for patients with relapsed or refractory chronic lymphocytic leukemia, Paolo Ghia, MD, of the Universita Vita-Salute San Raffaele, and other researchers conducted a phase III randomized, multicentric ASCEND study, testing acalabrutinib monotherapy in comparison with physician’s choice of standard regimens in patients R/R CLL.
High Response Rate Seen With Concurrent Ibrutinib Plus CAR T-Cell Therapy in High-Risk CLLJune 26th 2019
Significant activity was observed when ibrutinib was administered concurrently with CD19-directed CAR T-cell therapy compared with separately in patients with high-risk relapsed/refractory chronic lymphocytic leukemia who had progressed on or were intolerant of ibrutinib. Data presented at the 15th International Conference on Malignant Lymphoma show a high response rate with this concurrent treatment.